JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Search

Schrodinger Inc

Cerrado

SectorSanidad

12.31 3.45

Resumen

Variación precio

24h

Actual

Mínimo

12.3

Máximo

12.39

Métricas clave

By Trading Economics

Ingresos

169M

136M

Ventas

33M

87M

BPA

-0.18

Margen de beneficios

155.644

Empleados

850

EBITDA

67M

36M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+47.3% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

40M

867M

Apertura anterior

8.86

Cierre anterior

12.31

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

155 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Schrodinger Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 may 2026, 23:47 UTC

Ganancias

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3 may 2026, 22:35 UTC

Ganancias

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3 may 2026, 23:39 UTC

Charlas de Mercado

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3 may 2026, 23:34 UTC

Charlas de Mercado

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3 may 2026, 23:32 UTC

Ganancias

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3 may 2026, 23:30 UTC

Charlas de Mercado

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3 may 2026, 23:20 UTC

Charlas de Mercado

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3 may 2026, 23:16 UTC

Adquisiciones, fusiones, absorciones

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3 may 2026, 22:57 UTC

Adquisiciones, fusiones, absorciones

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3 may 2026, 22:57 UTC

Adquisiciones, fusiones, absorciones

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3 may 2026, 22:57 UTC

Adquisiciones, fusiones, absorciones

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3 may 2026, 22:57 UTC

Adquisiciones, fusiones, absorciones

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3 may 2026, 22:57 UTC

Adquisiciones, fusiones, absorciones

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3 may 2026, 22:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

3 may 2026, 22:45 UTC

Charlas de Mercado

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3 may 2026, 22:20 UTC

Ganancias

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3 may 2026, 22:08 UTC

Ganancias

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3 may 2026, 22:05 UTC

Ganancias

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3 may 2026, 22:05 UTC

Ganancias

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3 may 2026, 22:05 UTC

Ganancias

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3 may 2026, 22:04 UTC

Ganancias

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3 may 2026, 22:03 UTC

Ganancias

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3 may 2026, 22:03 UTC

Ganancias

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3 may 2026, 22:02 UTC

Ganancias

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3 may 2026, 22:02 UTC

Ganancias

NAB 1H Cash Earnings A$2.64B>NAB.AU

3 may 2026, 22:02 UTC

Ganancias

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3 may 2026, 22:01 UTC

Ganancias

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3 may 2026, 22:01 UTC

Ganancias

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3 may 2026, 22:01 UTC

Ganancias

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3 may 2026, 15:06 UTC

Ganancias

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Comparación entre iguales

Cambio de precio

Schrodinger Inc previsión

Precio Objetivo

By TipRanks

47.3% repunte

Estimación a 12 Meses

Media 18.25 USD  47.3%

Máximo 20 USD

Mínimo 13 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Schrodinger Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

4

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

23.27 / 26.13Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Very Strong Bullish Evidence

Sentimiento

By Acuity

155 / 347 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat